Anavex Life Sciences Corp (AVXL)

[Hosai]

Dr Jin only joined in March 2023. However he oversaw the Sept 2023 PR which found that the primary ADAS-COG end point had a 2.26 in 100 chance that the improvements in drug arm were due to chance and the secondary end point had a 1.75 in 100 chance of the improvements in drug arm being due to chance.

Also "The clinical effect was complemented by two independent biomarkers: A significant reduction in pathological amyloid beta levels in plasma1, as well as a significant slowing in the rate of pathological brain atrophy2 on MRI (Magnetic Resonance Imaging)3 scans.".

The reduction in brain volume reduction found via MRI had a 5 in 10,000 (or 1 in 2,000) chance of the improvements being due to chance.

Dr Jin was in charge for all these figures and he has over 20 years experience with FDA considering and analyzing alzherimers trials.
Imo as there is a lot of evidence that the drug is safe and the alternative approved drugs are fairly poor, even if the co-primary end point whch we don't know yet was not met at all these results are good enough that the drug should be approved.